Literature DB >> 7229908

Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

L B Sheiner, S L Beal.   

Abstract

Individual pharmacokinetic par parameters quantify the pharmacokinetics of an individual, while population pharmacokinetic parameters quantify population mean kinetics, interindividual variability, and residual intraindividual variability plus measurement error. Individual pharmacokinetics are estimated by fitting individual data to a pharmacokinetic model. Population pharmacokinetic parameters are estimated either by fitting all individual's data together as though there was no individual kinetic differences (the naive pooled data approach), or by fitting each individual's data separately, and then combining the individual parameter estimates (the two-stage approach). A third approach, NONMEM, takes a middle course between these, and avoids shortcomings of each of them. A data set consisting of 124 steady-state phenytoin concentration-dosage pairs from 49 patients, obtained in the routine course of their therapy, was analyzed by each method. The resulting population parameter estimates differ considerably (population mean Km, for example, is estimated as 1.57, 5.36, and 4.44 micrograms/ml by the naive pooled data, two-stage, and NONMEN approaches, respectively). Simulations of the data were analyzed to investigate these differences. The simulations indicate that the pooled data approach fails to estimate variabilities and produces imprecise estimates of mean kinetics. The two-stage approach produces good estimates of mean kinetics, but biased and imprecise estimates of interindividual variability. NONMEN produces accurate and precise estimates of all parameters, and also reasonable confidence intervals for them. This performance is exactly what is expected from theoretical considerations and provides empirical support for the use of NONMEM when estimating population pharmacokinetics from routine type patient data.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7229908     DOI: 10.1007/bf01060053

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  10 in total

1.  A study of the pharmacokinetics of phenytoin (diphenylhydantoin) in epileptic patients, and the development of a nomogram for making dose increments.

Authors:  A Richens
Journal:  Epilepsia       Date:  1975-11       Impact factor: 5.864

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

4.  Modelling of individual pharmacokinetics for computer-aided drug dosage.

Authors:  L B Sheiner; B Rosenberg; K L Melmon
Journal:  Comput Biomed Res       Date:  1972-10

5.  Micro-determination of plasma diphenylhydantoin by gas-liquid chromatography.

Authors:  J Gordos; J Schäublin; P Spring
Journal:  J Chromatogr       Date:  1977-03-01

6.  Serum-phenytoin levels in management of epilepsy.

Authors:  A Richens; A Dunlop
Journal:  Lancet       Date:  1975-08-09       Impact factor: 79.321

7.  On the stochastic modeling of tracer kinetics.

Authors:  J H Matis; H D Tolley
Journal:  Fed Proc       Date:  1980-01

8.  Letter: Phenytoin dosage nomogram.

Authors:  L Lund; G Alvan
Journal:  Lancet       Date:  1975-12-27       Impact factor: 79.321

9.  Individualization of phenytoin dosage regimens.

Authors:  T M Ludden; J P Allen; W A Valutsky; A V Vicuna; J M Nappi; S F Hoffman; J E Wallace; D Lalka; J L McNay
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

10.  Predictability of phenytoin serum levels by nomograms and clinicians.

Authors:  S Vozeh; A Koelz; E Martin; H Magun; G Scollo-Lavizzari; F Follath
Journal:  Eur Neurol       Date:  1980       Impact factor: 1.710

  10 in total
  119 in total

1.  Variability of the model-independent AUC: the one sample per individual case.

Authors:  W Jawień
Journal:  J Pharmacokinet Biopharm       Date:  1999-08

2.  Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.

Authors:  Mark Sale; Brian M Sadler; Daniel S Stein
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

3.  Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?

Authors:  J P Hing; S G Woolfrey; D Greenslade; P M Wright
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

4.  Hydralazine dose-response curve analysis.

Authors:  D A Graves; K T Muir; W Richards; B W Steiger; I Chang; B Patel
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

5.  Bayesian Experimental Design for Long-Term Longitudinal HIV Dynamic Studies.

Authors:  Yangxin Huang; Hulin Wu
Journal:  J Stat Plan Inference       Date:  2008-01-01       Impact factor: 1.111

6.  Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.

Authors:  Elodie L Plan; Alan Maloney; France Mentré; Mats O Karlsson; Julie Bertrand
Journal:  AAPS J       Date:  2012-04-14       Impact factor: 4.009

Review 7.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

8.  Covariance analysis of laboratory variance in steady-state serum phenytoin concentrations.

Authors:  H Costeff; Z Groswasser; N Soroker; G van Belle
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

9.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

Review 10.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

Authors:  Stephen B Duffull; Daniel F B Wright; Helen R Winter
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.